Pulmatrix Valuation
| PULM Stock | USD 2.57 0.05 1.91% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Pulmatrix holds a recent Real Value of $4.42 per share. The prevailing price of the company is $2.57. Our model determines the value of Pulmatrix from analyzing the company fundamentals such as Return On Equity of -0.79, shares owned by institutions of 9.40 %, and Shares Outstanding of 3.65 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pulmatrix's valuation include:
Price Book 1.9677 | Enterprise Value | Enterprise Value Ebitda 1.5719 | Price Sales 3.1 K | Enterprise Value Revenue 22.4001 |
Undervalued
Today
Please note that Pulmatrix's price fluctuation is risky at this time. Calculation of the real value of Pulmatrix is based on 3 months time horizon. Increasing Pulmatrix's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pulmatrix stock is determined by what a typical buyer is willing to pay for full or partial control of Pulmatrix. Since Pulmatrix is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pulmatrix Stock. However, Pulmatrix's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.57 | Real 4.42 | Target 10.0 | Hype 2.47 | Naive 2.32 |
The intrinsic value of Pulmatrix's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pulmatrix's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pulmatrix helps investors to forecast how Pulmatrix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pulmatrix more accurately as focusing exclusively on Pulmatrix's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pulmatrix's intrinsic value based on its ongoing forecasts of Pulmatrix's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pulmatrix's closest peers.
Pulmatrix Cash |
|
About Pulmatrix Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Pulmatrix. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Pulmatrix based exclusively on its fundamental and basic technical indicators. By analyzing Pulmatrix's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Pulmatrix's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pulmatrix. We calculate exposure to Pulmatrix's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pulmatrix's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 736 K | 772.8 K | |
| Pretax Profit Margin | (1.10) | (1.16) | |
| Operating Profit Margin | (1.13) | (1.18) | |
| Net Loss | (1.10) | (1.16) | |
| Gross Profit Margin | 0.07 | 0.08 |
Pulmatrix Current Valuation Indicators
Pulmatrix's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Pulmatrix's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pulmatrix, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pulmatrix's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pulmatrix's worth.When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Will Pharmaceuticals sector continue expanding? Could Pulmatrix diversify its offerings? Factors like these will boost the valuation of Pulmatrix. Anticipated expansion of Pulmatrix directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulmatrix data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Pulmatrix's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulmatrix should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Pulmatrix's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.